Events
8th Congress of the International Boiron Society
8th of may, 2019
Heidelberg, Germany
Professor Rachel Nechuchstai of the Hebrew University in Jerusalem presented at the 8th Congress of the International Boiron Society in May a lecture entitled “The liability of the NEET proteins’ iron sulphur cluster: biomedical implications”. Professor Nechuchstai presented data generated in part through the close collaboration with ENYO Pharma on this topic.
EASL (European Association for the Study of the Liver)
10-14 April, 2019
Vienna, Austria
ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.
China Healthcare Investment Conference
26-28 March, 2019
Shanghai
ENYO Pharma has attended the China Healthcare Investment Conference from the 26th to the 28th of March, 2019. It was a great opportunity to initiate several financing and partneurship discussions.
J.P. Morgan 37th Annual Healthcare Conference
7 – 10 January, 2019
San Francisco, USA
“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.” (jpmorgan.com)
Immunotherapies for Infectious Diseases Congress
10 – 11 December, 2018
Lyon, France
ENYO Pharma’s CSO Eric Meldrum is participating today at the I4ID Congress (Immunotherapies for Infectious Diseases Congress) in Lyon, France. I4ID Congress is dedicated to Host-Directed Therapies to fight infectious diseases. During this event, Eric will present new data from ENYO Pharma preclinical programmes to exemplify the power of ENYO Pharma’s drug discovery approach.
“The 2nd edition I4ID2018, follows the success of the first edition,
Latest Press Release 